

15/c

I hereby certify that this correspondence is being
facsimile transmitted to the United States Patent
and Trademark Office on April 17, 2003

AMENDMENT UNDER 37 CFR §1.111 *jm*
Examining Group 1642
Patent Application
Docket No. GEN-T111XC3D1
Serial No. 09/853,526 *4/24/03*

Frank C. Eisenschenk
Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Christopher H. Yaen
Art Unit : 1642
Applicants : Daniel Cohen, Marta Blumenfeld, Ilya Chumakov, Lydie Bougueleret
Serial No. : 09/853,526
Filed : May 11, 2001
Conf. No. : 7147
For : Prostate Cancer Gene

Assistant Commissioner for Patents
Washington, D.C. 20231

AMENDMENT UNDER 37 CFR §1.111

Sir:

A Petition and Fee for a two-month Extension of Time through and including April 21, 2003,
accompanies this Amendment.

In response to the Office Action dated November 19, 2002, please amend the above-
identified patent application as follows:

In the Claims

50. (AMENDED) A method of binding an antibody to a PG1 polypeptide, comprising the
steps of:

- a) ~~obtaining said antibody and said PG1 polypeptide from a biological sample;~~
and

FACSIMILE COVER SHEET

FAX RECEIVED

APR 18 2003

GROUP 1600

SALIWANCHIK, LLOYD & SALIWANCHIK

A Professional Association
2421 N.W. 41st Street
Suite A-1
Gainesville, FL 32606

Telephone (352) 375-8100
Facsimile (352) 372-5800

OFFICIAL

TO: Examiner Christopher H. Yaen

FROM: Frank C. Eisenschenk, Ph.D.
(Reg. No. 45,332)COMPANY: U.S. Patent & Trademark Office,
Examining Group 1642

DATE: April 17, 2003

FAX NO.: (703) 308-4242

NO. OF PAGES: 11
(INCLUDING COVER SHEET)

SUBJECT/MESSAGE: U.S. Patent Application Docket No. GEN-T111XC3D1
PROSTATE CANCER GENE
(Cohen *et al.*)
Serial No. 09/853,526, filed May 11, 2001

THIS IS AN OFFICIAL DOCUMENT.
PLEASE DELIVER IMMEDIATELY. Thank you.

Enclosures: Amendment Under 37 CFR §1.111 (9 pages)
Petition and Fee for Extension of Time Under 37 CFR §1.136(a) (1 page)

The information contained in this facsimile message is intended only for the personal and confidential use of the designated recipients named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message by mail. Thank you.

If you do not receive all pages or if any transmission is not legible, call the sender at (352) 375-8100.